logo

XENE

Xenon Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)

XENE fundamentals

Xenon Pharmaceuticals (XENE) released its earnings on Nov 3, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -1.15 (YoY -41.98%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-1.15
-41.98%
Report date
Nov 3, 2025
XENE Earnings Call Summary for Q3,2025
  • Phase III Milestone: 380 patients randomized in X-TOLE2, targeting 2026 readout for azetukalner in focal onset seizures.
  • Therapeutic Expansion: Azetukalner in MDD and BPD trials (X-NOVA2, X-CEED) with Phase I pain programs advancing.
  • Financial Strength: $555M cash, sufficient for operations into 2027; new CFO driving commercial readiness for 2027 launch.
  • Differentiation: AZK's QD dosing, no titration, and mood benefits position it for 30-40% U.S. epilepsy market share.
EPS
Revenue

Revenue & Expenses

Key Indicators

Xenon Pharmaceuticals (XENE) key financial stats and ratios, covering profitability, financial health, and leverage.
Xenon Pharmaceuticals (XENE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Xenon Pharmaceuticals (XENE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Xenon Pharmaceuticals (XENE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Xenon Pharmaceuticals (XENE) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Xenon Pharmaceuticals (XENE) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield